This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain | The Motley Fool

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.